VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2020 | KEYNOTE-204 in R/R classical Hodgkin lymphoma

John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, ON, details the results of the KEYNOTE-204 study (NCT02684292) which aimed to determine the benefit of pembrolizumab against brentuximab vedotin in patients with relapsed or refractory classical Hodgkin lymphoma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter